ARMD.1.H.iPSC.2
RIi013-A
General
Cell Line |
|
| hPSCreg name | RIi013-A |
| Cite as: | RIi013-A (RRID:CVCL_B962) |
| Alternative name(s) |
ARMD.1.H.iPSC.2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
STBCi110-A (SFC116-03-01) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration |
| Last update | 8th December 2017 |
| User feedback | |
Provider |
|
| Generator |
Royan Institute (RI)
Contact:
Embryonic Stem Cell Biology |
| Derivation country | Iran |
External Databases |
|
| Cellosaurus | CVCL_B962 |
| Wikidata | Q54750538 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Ethics
| Please provide contact information of the holder of the original Donor Information Sheet. | |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please provide the contact information | |
| Alternatives to consent | |
| Details on restriction to research project | |
| How may genetic information associated with the cell line be accessed? | |
| Please describe how access is provided: | |
| Contact data, institution, or website: | |
| Name of accrediting authority involved? | |
| Approval number | |
| Name of accrediting authority involved? | |
| Approval number | |
| Please describe: | |
| Further constraints on use | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Constraints for use or distribution |
hIPSC Derivation
General |
|
| Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
Unknown |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||||||||||||||||||||
| Medium |
Other medium:
Base medium: DMEM F/12
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SSEA-3 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XX
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.